At the time of writing, Astrazeneca plc ADR [AZN] stock is trading at $68.11, down -0.44%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The AZN shares have gain 1.95% over the last week, with a monthly amount glided 0.65%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 5, April 2024, ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors. In a post published today on Yahoo Finance, Based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s ENHERTU that showed clinically meaningful responses across a broad range of tumors.
From an analyst’s perspective:
Astrazeneca plc ADR [NASDAQ: AZN] stock has seen the most recent analyst activity on February 08, 2024, when Deutsche Bank downgraded its rating to a Sell. Previously, Morgan Stanley started tracking the stock with Overweight rating on January 23, 2024, and set its price target to $85. Jefferies downgraded its rating to a Hold and decreased its price target to $70 on January 03, 2024. HSBC Securities initiated its recommendation with a Buy and recommended $78 as its price target on December 18, 2023. Jefferies upgraded its rating to Buy for this stock on September 25, 2023, and upped its price target to $80. In a note dated July 14, 2023, HSBC Securities initiated an Buy rating.
For the past year, the stock price of Astrazeneca plc ADR fluctuated between $60.47 and $76.56. Currently, Wall Street analysts expect the stock to reach $80.5 within the next 12 months. Astrazeneca plc ADR [NASDAQ: AZN] shares were valued at $68.11 at the most recent close of the market. An investor can expect a potential return of 18.19% based on the average AZN price forecast.
Analyzing the AZN fundamentals
According to Astrazeneca plc ADR [NASDAQ:AZN], the company’s sales were 45.81B for trailing twelve months, which represents an 7.29% jump. Gross Profit Margin for this corporation currently stands at 0.82% with Operating Profit Margin at 0.18%, Pretax Profit Margin comes in at 0.15%, and Net Profit Margin reading is 0.13%. To continue investigating profitability, this company’s Return on Assets is posted at 0.06, Equity is 0.16 and Total Capital is 0.12. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.73.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 67.63 points at the first support level, and at 67.15 for the second support level. However, for the 1st resistance point, the stock is sitting at 68.38, and for the 2nd resistance point, it is at 68.64.
Astrazeneca plc ADR [AZN] reported earnings per share of $0.72 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $0.79/share, meaning a difference of -$0.07 and a surprise factor of -8.90%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were $0.87 per share as compared to estimates of $0.84 per share, a difference of $0.03 representing a surprise of 3.60%.
Ratios To Look Out For
It is important to note that Astrazeneca plc ADR [NASDAQ:AZN] has a current ratio of 0.82. Further, the Quick Ratio stands at 0.64, while the Cash Ratio is 0.19. Considering the valuation of this stock, the price to sales ratio is 4.61, the price to book ratio is 5.39 and price to earnings (TTM) ratio is 35.69.
